Abstracts mentioned:

• 01:31 LINERIXIBAT SIGNIFICANTLY IMPROVES CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: RESULTS OF THE PIVOTAL PHASE 3 GLISTEN TRIAL https://gutflix.eu/r/fVuDoNr9dIwj
• 03:08 PEGOZAFERMIN DEMONSTRATED ROBUST HISTOLOGICAL IMPROVEMENT AND BENEFIT IN HEPATIC AND METABOLIC BIOMARKERS: RESULTS FROM A 48-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL (ENLIVEN) https://gutflix.eu/r/519I7XXve4lO
• 03:45 The future of MASLD https://stream.ueg.eu/week2025/crs/the-future-of-masld
• 04:40 PROPHYLACTIC ANTIBIOTICS REDUCE POST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY INFECTIOUS COMPLICATIONS IN PATIENTS WITH DISTAL MALIGNANT BILIARY OBSTRUCTION: A MULTICENTER PROPENSITY SCORE MATCHED STUDY https://gutflix.eu/r/GNCqFKj3mzbHhttps://gutflix.eu/r/GNCqFKj3mzbH
• 05:10 BILE LIQUID BIOPSY IN PANCREATOBILIARY TUMORS: A NOVEL APPROACH TO DETECT ACTIONABLE MUTATIONS https://gutflix.eu/r/ueS6ujLav2uo
• list text here06:50: SIMVASTATIN IN THE PREVENTION OF RECURRENT PANCREATITIS: THE SIMBA TRIAL https://gutflix.eu/r/v8NVi0M5Atw9
• 08:25 Rising Stars from Europe and Japan: Metabolic liver diseases https://gutflix.eu/r/EqP6ydAyHa7Z ARTIFICIAL INTELLIGENCE FOR COMPREHENSIVE PANCREATIC LESION PROFILING: MULTICENTER VALIDATION OF SOLID/CYSTIC LESION DETECTION/CHARACTERIZATION AND IPMN GRADING M. Mascarenhas-Saraiva